EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study

Susan L Ford, Franco Felizarta iD, Kelong Han, Kehui Wang, Herta Crauwels iD, Anna Dari, Mar Masia iD, Miguel Garcia Deltoro iD, Olaf Degen, Jonathan B Angel iD, Chiu-Bin Hsiao iD, Carolina Acuipil und 5 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae620 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Susan L Ford und 16 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare, J&J Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cabotegravir + rilpivirine (CAB + RPV) administered via intramuscular gluteal injections is the first complete long-acting regimen for maintaining human immunodeficiency virus type 1 (HIV-1) virologic suppression. We present substudy results on short-term repeat intramuscular CAB + RPV long-acting thigh injections in participants with ≥3 years of experience with gluteal administration during the ATLAS–2M study.

Methods

Substudy phases included screening, thigh injection (day 1–week 16), and return to gluteal injection (week 16–week 24). The injection schedule was unchanged from the main study. Outcomes included pharmacokinetics, safety, tolerability, efficacy, and patient-reported outcomes. Pharmacokinetic parameters were determined using noncompartmental analysis and mixed-effects modeling. Population pharmacokinetic simulations were performed.

Results

There were 118 participants. In the arm that received injections every 2 months (Q2M), first CAB thigh injection including area under the concentration–time curve and maximum observed concentration (Cmax) and first RPV thigh injection Cmax and all last RPV thigh injection parameters were statistically higher vs gluteal injections (paired comparison). No significant differences occurred with once-monthly (QM) dosing. No participants had HIV-1 RNA ≥50 copies/mL after thigh injections. Overall, 4%–7% of injection site reactions (ISRs) were grade 3. Five participants withdrew due to an ISR or injection intolerability. Overall, 30% preferred thigh vs gluteal injections. Simulations demonstrated the potential for chronic/continuous QM or ≤2 consecutive Q2M thigh injections.

Conclusions

These data demonstrate the potential use of chronic/continuous QM and rotational/short-term QM or Q2M (≤4 months of continuous dosing), CAB + RPV long-acting intramuscular thigh administration for HIV-1 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsHIV-1Anti-HIV AgentsPyridonesHumansMaleAdultFemaleThighInjections, IntramuscularMiddle AgedViral LoadDiketopiperazines

Stichwörter der Autor:innen

HIVcabotegravirlong-actingrilpivirinethigh

Substanzen

RilpivirinecabotegravirAnti-HIV AgentsPyridonesDiketopiperazines

Autor:innen und Institutionen

  • GSK, Durham, North Carolina, USA.
  • Private practice of Franco Felizarta, MD, Bakersfield, California, USA.
  • GSK, Collegeville, Pennsylvania, USA.
  • Janssen Research & Development, Beerse, Belgium.
  • Infectious Diseases Section, Department of Internal Medicine, Hospital General Universitario de Elche, Elche, Alicante, Spain.
  • Centro de Investigación en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Franco Felizarta, Herta Crauwels, Mar Masia, Miguel Garcia Deltoro, Jonathan B Angel, Chiu-Bin Hsiao

Förderung

  • ViiV Healthcare
  • J&J Innovative Medicine

Zitieren

APA

Ford, S. L., Felizarta, F., Han, K., Wang, K., Crauwels, H., Dari, A., Masia, M., Garcia Deltoro, M., Degen, O., Angel, J. B., Hsiao, C. B., Acuipil, C., Kolobova, I., Harrington, C., Rimler, K., Spreen, W., & D'Amico, R. (2025). Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae620

Vancouver

Ford SL, Felizarta F, Han K, Wang K, Crauwels H, Dari A, et al. Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae620

BibTeX
@article{Ford2025,
  author = {Ford, Susan L and Felizarta, Franco and Han, Kelong and Wang, Kehui and Crauwels, Herta and Dari, Anna and Masia, Mar and Garcia Deltoro, Miguel and Degen, Olaf and Angel, Jonathan B and Hsiao, Chiu-Bin and Acuipil, Carolina and Kolobova, Irina and Harrington, Conn and Rimler, Kelly and Spreen, William and D'Amico, Ronald},
  title = {Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae620}
}
Kostenlos starten →